Oncotelic Therapeutics to Present Sapu003 Breast Cancer Treatment Data at 2025 San Antonio Symposium

Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that Sapu003, an investigational intravenous Deciparticle formulation of everolimus developed by Sapu Nano, has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium scheduled for December 9-12, 2025. The acceptance of this presentation represents a significant milestone for the clinical development of this novel therapeutic approach for hormone receptor-positive, HER2-negative metastatic breast cancer.

Sapu003 represents a technological advancement in cancer treatment through its Deciparticle nanotechnology platform, which aims to improve the bioavailability of everolimus while reducing toxicity and enhancing tumor penetration. This formulation addresses critical limitations of current mTOR inhibitor therapies, potentially offering improved therapeutic outcomes for patients with HR⁺/HER2⁻ metastatic breast cancer, renal cell carcinoma, and neuroendocrine tumors. The development of Sapu003 emerges from the joint venture between Oncotelic Therapeutics and Dragon Oversea, combining expertise in nanomedicine and oncology drug development.

The presentation at the prestigious San Antonio Breast Cancer Symposium provides validation of the scientific merit of Sapu003 and offers an important platform for sharing clinical data with the global oncology community. This symposium represents one of the most significant gatherings of breast cancer researchers and clinicians worldwide, making it an ideal venue for presenting advancements in metastatic breast cancer treatment. The timing of this presentation aligns with growing interest in improved formulations of existing cancer therapies that can enhance efficacy while minimizing adverse effects.

For patients with HR⁺/HER2⁻ metastatic breast cancer, the development of Sapu003 could potentially address unmet needs in treatment options that balance effectiveness with manageable side effect profiles. The nanotechnology approach employed in Sapu003's Deciparticle formulation represents an emerging trend in oncology drug development, focusing on improving drug delivery systems to maximize therapeutic benefit. Additional information about Oncotelic Therapeutics is available through the company's newsroom at https://ibn.fm/OTLC.

The broader implications of successful Sapu003 development extend beyond breast cancer treatment, as the Deciparticle platform technology could potentially be applied to other cancer types and therapeutic agents. This presentation at a major scientific conference marks an important step in the clinical validation process and may influence future development decisions and potential regulatory pathways. The data presentation will contribute to the growing body of evidence supporting nanotechnology approaches in oncology therapeutics, potentially shaping treatment paradigms for metastatic breast cancer and other malignancies.